doi: 10.1161/01.RES.0000252802.25497.b7
© 2007 American Heart Association, Inc.
Reviews |
Platelets as Immune Cells
Bridging Inflammation and Cardiovascular Disease
From the Institute of Cardiovascular Molecular Research, University Hospital of the Rheinisch-Westfälische Technische Hochschule, Aachen, Germany.
Correspondence to Dr Christian Weber, Institut für Kardiovaskuläre Molekularbiologie, Pauwelsstrasse 30, 52074 Aachen, Germany. E-mail cweber{at}ukaachen.de
This Review is part of a thematic series on Mechanisms, Models, and In Vivo Imaging of Thrombus Formation, which includes the following articles:
Activation of Platelet Function Through G Protein–Coupled Receptors
Platelets as Immune Cells: Bridging Inflammation and Cardiovascular Disease
In Vivo Thrombus Formation
Platelet Adhesion
Platelet Inhibitors and Thrombus Formation
Bernhard Nieswandt and Ulrich Walter Guest Editors
 |
Abstract |
|---|
 Top Abstract IntroductionSurface Molecules Linking...Soluble Immune MediatorsMicrobicidal ProteinsPlatelets Are Active Players...ConclusionsReferences |
|---|
Beyond an eminent role in hemostasis and thrombosis, platelets are characterized by expert functions in assisting and modulating inflammatory reactions and immune responses. This is achieved by the regulated expression of adhesive and immune receptors on the platelet surface and by the release of a multitude of secretory products including inflammatory mediators and cytokines, which can mediate the interaction with leukocytes and enhance their recruitment. In addition, platelets are characterized by an enormous surface area and open canalicular system, which in concert with specialized recognition receptors may contribute to the engulfment of serum components, antigens, and pathogens. Platelet-dependent increases in leukocyte adhesion may not only account for an exacerbation of atherosclerosis, for arterial repair processes, but also for lymphocyte trafficking during adaptive immunity and host defense. This review compiles a selection of platelet-derived tools for bridging inflammation and vascular disease and highlights the molecular key components governing platelet-mediated mechanisms operative in immune surveillance, vascular remodeling, and atherosclerosis.
Key Words: platelets • inflammation • cardiovascular disease • chemokines • adhesion molecules
|
Introduction |
|---|
|
TopAbstractIntroductionSurface Molecules Linking...Soluble Immune MediatorsMicrobicidal ProteinsPlatelets Are Active Players...ConclusionsReferences |
|---|
Undoubtedly, blood platelets play an eminent role in hemostasis and thrombosis. However, their distinctive armament with proinflammatory mediators as well as the presence of surface receptors predominantly known for their involvement in inflammatory or immune processes clearly exceeds an exclusive function as mere players in these primary physiological processes. Platelets amount to measures of roughly 300 000 cells per microliter of blood and individually feature a cell volume of 7 fL and a mean surface area of 8 µm2. In aggregate, blood platelets thus display a larger total volume and surface area than the aggregate of all other leukocyte subtypes taken together. On activation, platelets exhibit the ability to release considerable quantities of secretory products and express a multitude of immune receptors on their membrane. In addition, platelets are characterized by an open canalicular system, which may contribute to the engulfment (and/or "filtration") of serum components, pathogens, or antigens. As protagonists (and more than supporting actors) in both inflammatory and immune processes reviewed herein, platelets represent an ideal and crucial link to explain the inseparability of thrombotic and inflammatory events, as it occurs in cardiovascular diseases such as atherosclerosis or atherothrombosis. This review summarizes the most important findings on the role of platelets according to their molecular key constituents with immune and/or inflammatory relevance, laying out a "toolbox" for the participation of platelets as immune cells, and gives an update of the intensively investigated involvement of platelets in inflammation and the immune system.
|
Surface Molecules Linking Platelets to the Immune System |
|---|
|
TopAbstractIntroductionSurface Molecules Linking...Soluble Immune MediatorsMicrobicidal ProteinsPlatelets Are Active Players...ConclusionsReferences |
|---|
P-Selectin
P-Selectin is an integral membrane glycoprotein expressed by platelets1 and endothelial cells2 but has also been recently found in macrophages of atherosclerotic plaques3 (Figure 1). Cellular activation leads to rapid redistribution from the secretory
-granules of platelets and Weibel–Palade bodies of endothelial cells to the plasma membrane.4 By binding its major ligand P-selectin glycoprotein ligand-1 (PSGL-1), P-selectin initiates the adhesion of platelets by establishing reversible bonds that transform tethering into rolling and subsequently allow firm arrest. Intravital microscopy in P-selectin–deficient and wild-type mice revealed that regardless of their stimulation platelets roll on activated endothelium in vivo, which requires endothelial but not platelet P-selectin.5,6 However, P-selectin on platelets is an important adhesion molecule for PSGL-1–bearing immune cells, as it mediates adhesion of activated platelets to monocytes, neutrophils, and lymphocytes, resulting in the formation of platelet/leukocyte complexes and, vice versa, supports leukocyte rolling and arrest on surface-adherent platelets.7–9 In vitro, activated platelets enhance tethering of lymphocytes to PNAd (peripheral lymph node addressin) and sustain lymphocyte rolling, even in the absence of functional L-selectin. In an animal model, platelets facilitate lymphocyte delivery to high endothelial venules (HEVs) by platelet P-selectin, which allows activated platelets to transiently form a bridge between lymphocytes and HEVs, thereby enabling lymphocytes to undergo subsequent ß2 integrin–dependent firm adhesion.7,10 This alternative adhesion pathway is sufficient to reestablish lymphocyte trafficking in L-selectin–deficient mice and restores a contact hypersensitivity immune response to cutaneous antigen. In a similar fashion, crosslinking of PSGL-1 on monocytes by platelet P-selectin induces upregulation and activation of ß1 and ß2 integrins and enhances monocyte recruitment to activated endothelium.11 Furthermore, most monocytes bind soluble platelet-derived P-selectin, which does not alter the expression of the 4ß1 integrin VLA-4 (Very-Late Antigen-4) on monocytes but enhances its adhesiveness. It has been inferred that PSGL-1/P-selectin interactions thereby promote the binding of VLA-4 to vascular cell adhesion molecule-1 (VCAM-1) during the sequential adhesion cascade that regulates monocyte trafficking to inflammatory and atherosclerotic lesion.12
|
The CC chemokine RANTES released by stimulated platelets can be immobilized and presented on activated endothelium, where it enhances monocyte recruitment13 (Figures 2 and 3
). The finding that endothelial deposition of RANTES by platelets is more effective in flow than in stasis led to the discovery that platelet P-selectin but not PSGL-1 was critical for the deposition of platelet-derived RANTES as a prerequisite for its arrest function on activated endothelium.14 Platelet activation encompasses multiple cellular responses, including the formation of platelet microparticles (Figure 3). The concept that RANTES deposition is supported by transient platelet microparticle interactions with endothelium may invoke a role of adhesion and/or signaling receptors in the delivery of RANTES. The diffuse distribution pattern of RANTES, which was not significantly colocalized with firmly adherent platelet microparticles, suggests a more important role of molecules inducing transient interactions rather than firm arrest. Indeed, blocking P-selectin but also GPIb or junctional adhesion molecule (JAM)-A reduced deposition of platelet-derived RANTES and subsequent monocyte arrest.15 Although chemokines presented on the endothelium trigger integrin activation, an additional mechanism has been proposed, by which P-selectin–mediated signaling directly activates integrin clustering. It has been proposed that crosslinking PSGL-1 induces clustering of lymphocyte function-associated antigen-1 (LFA-1) on Th1 cells16 and clustering of Mac-1 on neutrophils.17
|
|
In conjunction, these findings support the notion that P-selectin on platelets is crucial for the recruitment of immune cells by dual action as an adhesion and signaling molecule. It enables the close contact of platelets with inflammatory blood-borne cells and induces rolling of these cells that together with arrest chemokines entails the activation of integrins important in mediating firm adhesion. Furthermore, platelet P-selectin is instrumental in facilitating the delivery and immobilization of platelet-derived chemokines on activated or atherosclerotic endothelium as culprits for mononuclear cell infiltration. It will be subject to further investigation how ligands for P-selectin expressed on endothelial cells, possibly PSGL-1, and their modification under inflammatory conditions may contribute to these processes.
Integrins
Platelets express several integrins (Figure 1), eg, Vß3, 2ß1, 5ß1, or 6ß1, but IIbß3 (glycoprotein GPIIb/IIIa) is clearly the predominant one18,19 and has recently been found to be functionally active in mast cells and hematopoietic progenitors.20 By forming a bridge to adhesive proteins, such as fibrinogen, von Willebrand factor, or fibronectin, IIbß3 mediates arrest of activated platelets to adhesion molecules intercellular adhesion molecule (ICAM)-1 and Vß3 on endothelium (Figure 3), as indicated by in vitro studies.21 Integrins form an interface between extracellular membrane proteins and intracellular proteins, enabling bidirectional information transfer. Ligation of IIbß3 through multivalent ligands, eg, fibrinogen, leads to clustering and outside-in signaling, which is important in cytoskeletal rearrangement in the process of aggregation.22,23 The binding of the cytoplasmic tails of both subunits keeps IIbß3 in a resting state. Activation of platelets results in binding of the key regulator talin to the ß tail that in turn results in splaying of the and ß tails, and triggers an inside-out conformational signal for receptor activation and exposure of its ligand-binding pocket.24,25 Integrin IIbß3 links platelets to sites of injury in vessels through interaction with fibrinogen and von Willebrand factor, which in aggregate form a plug leading to hemostasis.
Another binding partner of IIbß3 has been shown to be CD40 ligand (CD40L) expressed on the membrane of activated platelets, which is important in stabilizing arterial thrombi.26 The KGD domain of sCD40L binds to IIbß3, triggering outside-in signaling by tyrosine phosphorylation of ß3.27 Thus, CD40L binds to IIbß3 in thrombosis and inflammation. Blocking IIbß3 by intravenous antagonists reduces the rise in inflammatory markers, such as C-reactive protein and interleukin (IL)-6, after coronary interventions and the antiinflammatory effects of this antagonism have been held responsible for long-term clinical benefits.28 Furthermore, a relation of IIbß3 to inflammation can be deduced by the finding that specific types of IIbß3 inhibitors can increase the release of platelet granules, despite inhibiting agonist-induced fibrinogen binding.29 By binding and possibly stabilizing, the active conformation of IIbß3 antagonists may be proinflammatory at suboptimal doses, but, by blocking platelet aggregation, they may inhibit inflammation and thrombosis, as is evident by reduced release of inflammatory mediators sCD40L (soluble CD40L) or RANTES.30,31 However, this may be particularly relevant under conditions of arterial injury, eg, after percutaneous intervention, with abundant platelet activation, whereas transient interactions of platelets may be sufficient during atherogenesis.
CD40 Ligand
Besides activating platelet IIbß3, CD40L (also termed CD154) plays a crucial role in pathogen clearance. As a trimeric transmembrane protein (Figure 1), it is structurally related to the cytokine tumor necrosis factor (TNF)- and was originally identified on stimulated T cells.32,33 Subsequently, platelets were found to upregulate CD40L on activation and aggregation via arachidonic acid-mediated gp91phox activation, which results in stimulation of endothelial cells through its cognate receptor CD40 and in increased expression of adhesion molecules and chemokines enhancing the recruitment of immune cells.34,35 These results prompted investigations that demonstrated the link of platelet-derived CD40L and atherosclerosis.36–39 The role of platelets has also been extended beyond inflammatory reactions or innate immunity. Ligation of CD40 by platelet-derived CD40L induces dendritic cell maturation, B-cell isotype switching, and augmentation of CD8+ T cell responses both in vitro and in vivo, causing enhanced protection against viral re-challenge.40 In contrast, depletion of platelets in wild-type mice results in decreased antigen-specific antibody production.40 Together with findings that platelets alone or low amounts of CD4+ T cells per se are not sufficient in the formation of germinal centers, although a combination of both is sufficient, led to the notion that platelets exert a sentinel function, enhancing signals required for robust adaptive humoral immunity.41 Platelet-derived or even soluble CD154 has recently been found to be sufficient for the initiation and induction of vascularized allograft (eg, cardiac) rejection independent of cell-bound sources of this molecule.42 Platelet-derived sCD40L is also elevated and biologically active in sickle cell anemia. The participation of sCD40L in sickle cell anemia plasma–induced production of B cells, tissue factor, and ICAM-1 suggests that CD40L may contribute to the chronic inflammation and increased thrombotic activity known to occur in this disorder.43
CD40
Serving as the receptor for CD154 (CD40L), CD40 is a trimeric transmembrane protein and belongs to the TNF receptor superfamily (Figure 1). CD40 is displayed by a wide range of immune cells including monocytes, dendritic cells, and B cells and contributes to the development of the acquired immune response, depending on its activation and subsequent signal transduction by CD40L.44 CD40 is not only constitutively expressed on platelets but plays an important role in confining the inflammatory response induced by CD40L. This occurs by inducing the cleavage of CD40L, which results in a 18-kDa soluble form without an inflammatory effect on endothelial cells.37,45 In contrast, sCD40L retains its ability to stimulate platelets through CD40. Similarly, T-cell bound CD40L can activate platelets and triggers the release of RANTES, which is followed by enhanced T-cell recruitment, epitomizing a proinflammatory feedback loop.38 In addition, sCD40L can enhance platelet aggregation, and platelet-leukocyte conjugation, and can potentiate agonist-induced release of reactive oxygen intermediates by platelets.46 Whether platelet CD40 or CD40L prevail in promoting vascular inflammation remains to be determined using bone marrow chimeras or platelet-specific deletion.
Intercellular Adhesion Molecule 2
ICAM-2 is a 55-kDa member of the immunoglobulin (Ig) superfamily of adhesion molecules, composed of 2 N-terminal Ig domains with 35% homology to ICAM-1, a transmembrane domain, and a short cytoplasmic tail. As a counter-receptor for the leukocyte ß2 integrin LFA-1 (Lß2, CD11a/CD18) and for the dendritic cell-specific, ICAM-grabbing nonintegrin (DC-SIGN), ICAM-2 is constitutively expressed on endothelial cells, most leukocytes, and platelets. Also expressed on platelets, DC-SIGN may participate to the engulfment of pathogens into platelets. Because ICAM-1 and ICAM-3 were not detectable, ICAM-2 was thought to be the principle ß2-integrin ligand present on platelets. Platelet-derived ICAM-2 is not upregulated on activation and has been shown to mediate lymphocyte-platelet adhesion via LFA-1 (or DC-SIGN) and may also contribute to the transition of neutrophil rolling into Mac-1–dependent firm arrest under flow conditions.47–49 Notably, posttranslational modification of ICAM-2 by physiologic sialylation renders it less able than endothelial ICAM-2 to support adherence of leukocytes.50
Junctional Adhesion Molecules
The F11 receptor (F11R, or JAM-A) was originally identified on platelets by the ability of the monoclonal antibody F11 to induce -granule release and shape change, which was attributable to crosslinking of the antigen with Fc
RII.51 Subsequent studies revealed that crosslinking of F11R without FcRII causes signal transduction by protein kinase C, adhesion, and formation of homodimers.52 The cDNA clone for this molecule was found in 1998, encoding a protein present within tight junctions of endothelial cells and termed junctional adhesion molecule-A (JAM-A).53 As the prototypic member of the JAM family, which forms a subclass within the Ig superfamily (Figure 1), JAM-A predominantly occurs as a homodimer.54,55 Trans interactions of platelet-derived JAM-A have been found to support the luminal deposition of platelet chemokines and to enhance the recruitment of leukocytes.15,56 Heterophilic binding of JAM-A by the integrin LFA-1 and its role in leukocyte transmigration in vitro and in vivo57,58 implies similar physiological functions during platelet/leukocyte interactions. By analogy, a third member of this family, JAM-C, was identified as a novel counter-receptor on platelets for the leukocyte ß2 integrin Mac-1 (Mß2, CD11b/CD18) mediating platelet-neutrophil interactions.59 In concert with the binding of Mac-1 to GPIb or fibrinogen presented by GPIIb/IIIa,48,60 this may particularly relevant for an inflammatory role of platelets in vascular injury and atherothrombosis. The relative and nonredundant contribution of different Ig adhesion molecules, in particular of JAMs, to the interactions of platelets with leukocytes and endothelial cells needs to be further clarified in detail.
Toll-Like Receptors
The human body is permanently challenged by different pathogens such as bacteria, viruses, fungi, and parasites. The initial clearance by innate immune responses is mediated by a group of receptors termed Toll-like receptors (TLRs). These type I integral membrane proteins (Figure 1) recognize common pathogen-associated molecular patterns and are characterized by an extracellular domain containing multiple leucine-rich repeats, a single transmembrane domain, and an intracellular Toll/IL-1 receptor domain, which on activation gathers multiple adaptor proteins and transduces signals.61 Typical ligands of TLRs comprise bacterial wall components, eg, lipopolysaccharide (LPS), which binds and activates TLR4 or nucleic acids. Intriguingly, TLRs can recognize structurally different molecules, as is evident by TLR4, which does not only serve as the receptor for LPS but also binds to paclitaxel, heat-shock proteins and fibrinogen with high affinity.61 TLRs are expressed by a variety of immune cells and some subtypes have recently been discovered on resting platelets and detected by immunohistochemistry of human coronary thrombi, suggesting a link between infectious immunity and arterial thrombosis.62 At least for TLR4, functional implications have been demonstrated in sepsis models. Similar to septicemia in humans, LPS has been shown to induce thrombocytopenia in a mouse model through TLR4-dependent sequestration of platelets to the lungs. This has been attributed to platelet activation via TLR4, which resulted in increased adhesiveness to fibrinogen but was not associated with increased expression of P-selectin, in line with the inability of LPS to induce platelet aggregation or calcium influx.63,64 Further support for the functional activity of platelet TLR4 comes from studies showing an in vivo role for LPS-stimulated platelets in triggering TNF- secretion and confirming the TLR4-dependent thrombocytopenia.65 TLR4 on human platelets might be particularly important in clinical scenarios involving specific serotypes of Escherichia coli as the responsible pathogen, eg, in hemolytic uremic syndrome (HUS), which is caused by enterohemorrhagic E coli (EHEC) infection.66 Other bacterial pathogens linking platelets to inflammatory responses include infections with rickettsia, which can activate platelets via TLR2 and lead to increased shedding of CD40L. In turn, this may entail direct activation of endothelial cells in vitro but may also reflect indirect effects by promoting inflammatory interactions between endothelial cells and platelets, involving a CX3CL1-related mechanism.67 Thus, TLR subtypes represent an increasingly appreciated class of immune receptors expressed in platelets, contributing to their immune cell function at the interface of infection and inflammatory thrombosis. It remains to be elucidated how platelet TLRs may be related to immune responses in the atherosclerotic plaque, known to involve some of the TLR ligands.
Chemokine Receptors
Chemokine receptors are 7-transmembrane proteins (Figure 1) that are coupled to G-protein heterotrimers and initiate signal transduction events leading to a multitude of cellular responses, in particular chemotaxis and adhesion.68–70 Some chemokine ligand/receptor pairs have been critically involved in both organ development and immune homeostasis. For instance, the targeted disruption of CXCR4 (to date, the only receptor for stromal cell–derived factor-1 [SDF-1]/CXCL12) resulted in embryonic lethality, with severe defects in hematopoiesis and vasculo- and cardiogenesis that closely resembled those seen in SDF-1–deficient mice, indicating that CXCR4 may be the major receptor for SDF-1.71–73 As insinuated by its universal expression pattern, the first evidence for the functional presence and membrane display of chemokine receptors on platelets was also provided for CXCR4. In vitro studies revealed its existence on the megakaryocytic lineage from progenitors to platelets and demonstrated that its ligand SDF-1 is able to trigger adhesion of megakaryocytes on endothelium and to induce migration of megakaryocyte precursors.74–77 Interestingly, although flow cytometry clearly confirmed the presence of CXCR4 on platelets, neither calcium influx nor upregulation of P-selectin and platelet aggregation occurred when washed platelets were used, providing a hint that the presence of chemokine receptors alone may not be sufficient for biological activity in platelets.75,77 Because platelets in plasma in turn react on stimulation with SDF-1, primarily because of decreasing cAMP levels,78 plasma components appeared to be required for platelet activation. Moreover, it has become apparent that intracellular signaling through CXCR4 changes during cell differentiation, eg, of B cells,79 and is affected by the differentiation-dependent expression of proteins interfering with signal transduction, eg, "regulators of G-protein signaling" (RGS). Indeed, RGS16 is upregulated during maturation of megakaryocytes and can inhibit SDF-1 signaling.80 Eventually, several studies have revisited platelet aggregation experiments with SDF-1 as a stimulus, demonstrating calcium influx.78,81–83 Under arterial flow conditions, SDF-1 induced weak aggregation that was strongly dependent on the presence of low amounts of the primary agonists ADP or thrombin that per se had only a slight effect.81 The same result could be obtained by stimulating platelets in plasma, in this case suggesting a role of low amounts of platelet agonists.78 A role for this mechanism may be envisioned during the development of atherosclerotic plaques, where SDF-1 is markedly detectable and could lead to platelet activation and formation of platelet-rich thrombi.83 Alternatively, SDF-1 may mediate the recruitment of circulating progenitors to support vascular regeneration, thrombus resolution, or remodeling.84,85 Independently, the functional expression of the chemokine receptors CCR1, CCR3, and CCR481,86 has been shown in platelets (Table 1). CCR4 is a receptor for MDC (CCL22) and TARC (CCL17). A comprehensive study showed calcium influx in platelets stimulated by TARC and other chemokines, as well as synergistic aggregation with TARC, MDC, RANTES (CCL5), and SDF-186,87 (Tables 1 and 2). Accordingly, findings that the chemokines TARC, MDC, and SDF-1 alone are not sufficient to induce platelet aggregation but need low levels of platelet agonists such as ADP or thrombin may explain such differences.81,88 Similar to the SDF-1/CXCR4 axis, CX3CR1, the receptor for fractalkine (CX3CL1) is functionally expressed on platelets and, independently of the presence of ADP, triggers Gi activation but not calcium influx, and triggers P-selectin upregulation and platelet adhesion to collagen and fibrinogen.89 Fractalkine may substantially contribute to platelet activation under conditions of vascular diseases, eg, vascular remodeling or atherosclerosis, where this chemokine is upregulated.90,91 Consistently, disruption of CX3CR1 in atherosclerosis prone mice results in a reduced plaque formation and a more stable plaque phenotype.92,93 However, the cell-specific role, relevance, and hierarchy of CX3CR1 and other chemokine receptors in platelets for activating or potentiating their immune functions will be further dissected by selective deletion in platelets.
|
|
|
Soluble Immune Mediators |
|---|
|
TopAbstractIntroductionSurface Molecules Linking...Soluble Immune MediatorsMicrobicidal ProteinsPlatelets Are Active Players...ConclusionsReferences |
|---|
Chemokines
Among the abundance of platelet-derived secretory products with inflammatory properties (Figure 2), the first member of the chemokine family was discovered in releasates from platelets and was named platelet factor 4 (PF4, CXCL4)94 The term chemokine was eponymously defined by their prominent feature as chemotactic cytokines, and coined approximately 20 years later by the identification of IL-8.95 Since then, a large family of more than 50 related proteins has evolved and has been classified according to their structure. Depending on the position of the first N-terminal cysteines that are either adjacent or separated by 1 amino acid residue, chemokines are divided into 2 large subfamilies (CC and CXC chemokines), with fractalkine (CX3CL1) displaying 3 amino acids to separate the cysteines and lymphotactin with 1 cysteine.70,96–98 In platelets, chemokines synthesized by megakaryocytes are stored within the
granules and may, in part, be expressed from mRNA transcripts that can be found in mature platelets.99 PF4 together with the ß-thromboglobulins (ß-TGs) are the most abundantly expressed platelet CXC chemokines and can be further divided by the absence (PF4) or presence (ß-TG) of an N-terminal ELR-motif, which enables binding to and activation of the chemokine receptors CXCR1 and CXCR2.100,101 In turn, PF4 differs from most other chemokines in that it exerts its biological activity at much higher concentrations. Both a specific proteoglycan102 and the G protein–coupled receptor CXCR3B103 have been reported to be responsible for its actions. Although PF4 has been found in other cell types, it appears to be most relevant in platelets because of the most substantial expression levels achieved. In the presence of appropriate costimuli, such as TNF-, PF4 induces exocytosis and firm neutrophil adhesion to endothelium.104,105 Additional biological characteristics include the inhibition of proliferation of many cell types, eg, endothelial cells,103,106 which may explain its angiostatic activity and myeloid progenitor cells.107 Like most chemokines, PF4 has a considerable affinity for glycosaminoglycans, eg, heparan sulfate, and interacts with other heparin-binding proteins.108–114 Notably, PF4 can block the activation of human progenitor cells by IL-8 because of its high affinity for IL-8.108,109 It appears that PF4 exerts its activity by interacting with these molecules resulting in differential effects that are not fully understood, eg, it blocks monocyte adhesion induced by IL-8, whereas it enhances monocyte adhesion induced by RANTES/CCL5.111 All of these chemokines are secreted by stimulated platelets (Table 2). Depending on their concentrations and affinities, heterophilic interactions of these chemokines may occur in preformed complexes of platelet granules, integrating synergistic or antagonistic cues for monocyte arrest, as proposed by the "chemokine interactome" (Figure 3).115 Because mice do not express an IL-8 ortholog, it will be interesting to see whether this principle can also be applied to the closest murine relative GRO-/CXCL1. The CC chemokine RANTES has been found by using a cDNA library enriched for T cell–specific sequences and causes the selective migration of human blood monocytes and T cells.116,117 Later, thrombin stimulation of human platelets was shown to result in the release of a preformed peptidic eosinophil–chemotactic activity that could be further purified to RANTES.118 RANTES clearly contributes to vascular inflammation in the context of atherosclerosis and neointima formation after vascular injury. In vitro perfusion of endothelial cells with activated platelets, their supernatants or platelet-derived microparticles leads to P-selectin–dependent endothelial deposition of RANTES (Figure 3) and increased monocyte recruitment on activated or early atherosclerotic endothelium. This could be reproduced in vivo, where injection of activated platelets in atherosclerosis-prone mice leads to P-selectin–dependent deposition of PF4 and RANTES and exacerbates atherosclerosis, whereas inhibition of RANTES receptors results in decreased lesion size, both in atherosclerosis and vascular injury.13–15,119,120 Furthermore a pivotal role of platelet-associated chemokine SDF-1 in vascular injury and remodeling has been established as immobilized platelets at the site of injury not only present SDF-1 thereby recruiting a subset of SMC progenitors but also secrete SDF-1 to support primary adhesion and migration of progenitor cells.84,85 As others have failed to detect a secretion of SDF-1 by human megakaryoblasts,82 the relevance of these findings in the human system needs to be confirmed. The group of platelet-derived chemokines with inflammatory and immune implications also includes TARC, which plays a crucial role in atopic dermatitis, because its release by platelets, attracting Th2 cells, correlates with disease activity.121 Collectively, platelets contain a multitude of chemokines that link platelet activation to the recruitment of immune cells by displaying or depositing chemokines on cell surfaces and activating their cognate receptors (Figure 2), resulting in enhanced integrin activity and thereby exacerbating vascular disease.122 The interference with immobilization sites or synergistic heteromerization of chemokines at sites of inflammation will be explored to provide novel avenues for therapeutic targeting.
Cytokines: Interleukin-1
Duplication of a common gene during evolution has produced three members of the IL-1 gene family: IL-1, IL-1ß, and IL-1 receptor antagonist (IL-1RA). IL-1 is the prototypic cytokine released by inflammatory cells. Whereas IL-1, because of the lack of a leader sequence, is primarily an intracellular regulator of proinflammatory events, its sibling IL-1ß123 is a secretable mediator and the structurally related protein IL-1Ra is a naturally occurring antagonist competing for the signaling receptor IL-1R1.124,125 In vitro and in vivo experiments have shown multiple biological effects of IL-1 including increased production of chemokines and upregulation of endothelial adhesion molecules.126 The synthesis, processing, secretion, and activity, particularly of IL-1ß, are tightly regulated processes. The administration of recombinant IL-1RA prevents inflammatory responses in animal models of inflammatory diseases and has been successful applied in rheumatoid arthritis.127–129 A role of IL-1ß for atherosclerosis has been proposed for many years. The expression of IL-1ß has been found to be increased in arteries of hyperlipidemic animals and in monocytes incubated with oxidized LDL, and in a transgenic animal model a high ratio of IL-1 to IL-1RA results in exacerbation of atherosclerotic lesions.130–132 Besides monocytes, platelets have been identified as major participants in the complex inflammatory development of atherosclerotic lesions.133 IL-1 activity of platelets was demonstrated by findings that activated human platelets and their releasates led to reactions typically for IL-1 such as IL-1–dependent cell proliferation or upregulation of adhesion molecules and chemokine expression by endothelial cells (Figure 2) that in turn could be blocked by antibodies against IL-1 or IL-1 receptor antagonists.134–137 Subsequently, it was demonstrated that platelets do not only contain preformed IL-1ß but that platelet activation induces rapid and sustained synthesis of pro-IL-1ß protein, which is shed in its mature form in membrane microvesicles and is controlled at the translational level by activation of platelet integrins.138,139 Unexpectedly, platelets were found not only to regulate IL-1 translation but also to possess a functional spliceosome, a complex that processes pre-mRNAs in response to integrin engagement or surface receptor activation.140 These findings indicate a hitherto unrecognized role of platelets in vascular inflammation or injury by connecting platelet activation, cytokine expression, and inflammatory responses.
|
Microbicidal Proteins |
|---|
|
TopAbstractIntroductionSurface Molecules Linking...Soluble Immune MediatorsMicrobicidal ProteinsPlatelets Are Active Players...ConclusionsReferences |
|---|
Antibacterial proteins, such as defensins, are components of the innate immune system found in many organisms and produced by a variety of cell types141 and are most abundantly secreted by neutrophils, but epithelial tissues and human airway tissue among others are a rich source as well.142–144 In addition to these cell types, human and rabbit platelets are known to store antibacterial proteins.145–147 These antibacterial proteins (Figure 2) are released from platelet
granules after stimulation with thrombin and were designated thrombocidins148 or thrombin-induced platelet microbicidal proteins.149 Partial characterization revealed that the bioactive protein moiety in human platelets was cationic and of low molecular weight145 and possesses potent bactericidal activity against a significant portion of Staphylococcus aureus isolates. Further characterization revealed 2 thrombocidins (TC-1 and -2), which correspond to C-terminally truncated forms of NAP-2 and CTAP-III that, in contrast to the full length forms, were bactericidal against some strains of Bacillus subtilis, S aureus, and fungicidal for Cryptococcus neoformans.150 Additional human chemokines, or their relative othologs, that exhibit antimicrobial activity in vitro have been identified.151–153 In line with these in vitro studies, full-length IL-8 did not exhibit antimicrobial activity, but C-terminal peptides of IL-8 revealed activity against bacteria, demonstrating that the amphipathic helix is the responsible structure.154 The cationic nature of these proteins is thought to be crucial to target and disrupt microbial membranes as they exhibit structural familiarity with cecropin-like peptides that affect their antimicrobial activity through formation of pore structures in phospholipids bilayers, leading to depolarization of the target membrane,151,155 but may additionally interfere with intracellular macromolecular synthesis.156 Because the concentrations that are needed for a relevant antimicrobial activity compared with that for inducing leukocyte migration are considerable, the question remains whether such concentrations can be achieved in vivo. This would have to be verified in relevant models of microbial infection. Among the CC as well as CXC chemokines with antibacterial activity, many are stored in platelets (SDF-1, GRO-, TARC, etc), providing an additional link for the in vivo relevance of platelets in coupling injury and inflammation. |
Platelets Are Active Players in Inflammatory and Immune Disease |
|---|
|
TopAbstractIntroductionSurface Molecules Linking...Soluble Immune MediatorsMicrobicidal ProteinsPlatelets Are Active Players...ConclusionsReferences |
|---|
Platelets in Infectious Disease
Interactions of bacterial pathogens with platelets take place in variety of clinical situations, endocarditis and cardiovascular disease being among the most intensively studied.157 Platelets interact with Gram-positive, Gram-negative bacteria and spirochetes, respond rapidly in the setting of vascular injury, aggregate after contact with bacteria through crossreactive immunodeterminants and plasma proteins, and have the ability to recognize pathogens via TLRs.62,158,159 These interactions have a common mechanism: bacteria target host fibronectin, collagen, or fibrinogen by proteins, anchored in the bacterial cell wall such as fibronectin-binding proteins (FnBPs),160 clumping factor,161 and platelet aggregation–associated protein (PAAP),162 which creates a protein bridge with a platelet receptor, usually GPIIb/IIIa or GPIb. This interaction in itself is insufficient for platelet activation but requires a circulating antibody specific for the bacterial surface protein to engage the platelet Fc
RIIa receptor,163,164 which induces platelet activation, aggregation, and thrombus formation. Because of these rapid responses, platelets accumulate in the setting of endovascular infections such as infectious endocarditis where platelets represent a significant portion of infected cardiac vegetations and emboli and have been traditionally interpreted as contributors to the progression and complications of infectious endocarditis.165,166 In an animal model for infectious endocarditis, the in vitro susceptibility to platelet derived antimicrobial peptides correlates well with disease severity and prognosis,146,167–169 but other mechanisms may be relevant for the critical role that platelets play for infections. Internalization of bacteria under resting conditions appears to be rare. When platelets are stimulated by agonists such as ADP or SDF-1, bacterial internalization is strongly increased and further enhanced under flow conditions.170,171 It remains controversial whether engulfment of the bacteria takes place within the open canalicular system, as suggested by staining with osmium black,172,173 or in separated vacuoles, as shown by the lack of typical protein composition of the vacuole membrane. Besides bacteria, platelets are able to internalize HIV-1 and lentivirus170,174,175 through CLEC-2 (C-type lectin-like receptor 2) and DC-SIGN expressed on platelets.176 The capture of HIV-1 by these cells amounts to a considerable threat for the immune system, as platelets can remain infectious over a prolonged time, indicating that platelets might facilitate HIV-1 dissemination. How this can be targeted in an effort to reduce viral load is an open question to be solved by future studies.
Atherosclerosis
Platelets and monocytes are thought to play a predominant role in the initiation and progression of atherogenesis.133 According to the many studies investigating the role of platelets in atherosclerosis, this disease involves many of the molecules outlined above, leading to platelet-facilitated immigration of monocytes and other mononuclear cells into the arterial wall.
In different mouse models for atherosclerosis (LDL-receptor–/– or apolipoprotein E–/–), P-selectin deficiency has been found to be associated with decreased formation of fatty streaks, which represent early atherosclerotic lesions,177 but a reduction in lesion area has also been found in more advanced atherosclerotic plaques.178,179 Because P-selectin is predominantly displayed on platelets and endothelium, bone marrow transplantation of P-selectin–/– was used to dissect the role of both cell types and revealed a significant contribution of platelets besides endothelial cells.180 P-selectin–dependent adhesion of platelets to monocytes results in circulating complexes with increased adhesion to endothelial cells under coronary flow conditions.181 Thus, transient P-selectin or PSGL-1 blockade at the time of arterial injury significantly limits plaque macrophage content and neointima formation in a dose-dependent manner after endothelial denudation injury of carotid arteries in apolipoprotein E–/– mice.182
P-Selectin is among the adhesion molecules of platelets and platelet-derived microparticles leading to prolonged contact with endothelial cells and deposition of chemokines that activate and arrest monocytes and exacerbate atherosclerotic lesions in mice.13–15,111,119 Moreover the strong proinflammatory mediator IL-1 is secreted by platelets and has an impact on atherosclerosis that is mediated at least by inducing alterations of the adhesive and chemotactic properties of endothelial cells.130,137,183–185
The glycoproteins GPIIb/IIIa and GPIb participate in platelet adhesion to the endothelium of atherosclerosis-prone mice that have not yet developed plaques and are involved in the deposition of chemokines from platelet-derived microparticles.15,186 As underlying mechanisms, the involvement of GPIb may encompass binding to von Willebrand factor to support platelet adhesion or to leukocyte Mac-1 to support platelet/leukocyte aggregates.60,181 The CD40–CD40L dyad is well known to play an important role in atherogenesis especially in inducing a plaque phenotype with a rich inflammatory infiltrate which is unstable and more likely prone to rupture with subsequent atherothrombosis and infarction.187,188 However, a direct link of platelet-derived CD40 or CD40L has not been yet established. Indeed, although an elevation of soluble CD40L in plasma has been useful to identify patients with unstable coronary artery disease at risk for acute syndromes and likely to benefit from antiplatelet treatment,189 an elegant population-based study revealed that sCD40L was not associated with subclinical atherosclerosis or atherosclerotic risk factors, but it was not determined whether sCD40L serves as a marker for future cardiac events.190 Thus, it is conceivable that sCD40L may be more suitable as a predictor of plaque vulnerability or acute syndromes with overt platelet activation.
In the context of vascular injury, platelets constitute repair modules that can cover sites of damages with exposed matrix and can present the necessary adhesive anchors and arrest chemokines to trigger the recruitment of circulating mononuclear and progenitor cells. These processes eventually contribute to the resolution of the damage and regeneration.122 As a recently discovered molecular link between thromboregulation and vascular inflammation, arterial wire injury was accompanied by a luminal upregulation of CD73/5'ecto-nucleotidase expression, which limits not only thrombus formation but also subsequent neointima formation, endothelial activation, and mononuclear cell infiltration.191
Atherosclerosis is known to be influenced by a variety of chemokines and chemokine receptors. Many of the chemokines including the primarily described proatherogenic chemokine MCP-1 are found in platelets (Table 2). At present, we have collected only indirect hints of the role platelets play in this process. Bone marrow reconstitution in chimeras can provide certain clues; however, this alone is not sufficient to delineate the role of certain chemokines and mediators, which can also be synthesized by other hematopoietic cells. Clearly, platelet-specific conditional knockout models will be most instructive and essential to discriminate between the role platelets and other blood cells play in these complex processes.133 Indeed, PF4-Cre transgenic mice allowing the generation of lineage-restricted gene knockouts to study megakaryocyte and platelet function in vivo have recently been described.192
For some platelet chemokines, a predictive value for the risk of atherosclerosis has been revealed. The G403A RANTES polymorphism, which results in increased RANTES transcription, has been associated with increased risk for coronary atherosclerosis.193 Moreover, a correlation between the deposition of PF4 in carotid atherosclerotic plaques with lesion severity and symptomatic disease suggested that persistent platelet activation may contribute to the evolution of atherosclerosis.194 Given that platelet chemokines are most effective when immobilized on activated endothelium, this highlights that an analysis of chemokine levels in plasma alone may not be suitable to reflect their function and to serve as biomarkers in atherosclerosis. The deposition of chemokines by transiently interacting platelets may also explain why inhibition of aggregation by antiplatelet drugs, which does not interfere with this process, is not useful in preventing atherogenesis.
|
Conclusions |
|---|
|
TopAbstractIntroductionSurface Molecules Linking...Soluble Immune MediatorsMicrobicidal ProteinsPlatelets Are Active Players...ConclusionsReferences |
|---|
A variety of common molecular themes have recently accumulated to provide an intriguing link for the involvement of platelets between thrombosis, inflammatory reactions, and immune responses. Through their display of multiple adhesion molecules and receptors as outlined above, platelets are ideally suited to react with sites with vascular injury, where they bind to subendothelial molecules or activated endothelium as a prerequisite for clotting and wound healing. However, the same adhesion molecules also enable platelets to support leukocyte arrest but also to facilitate recruitment of leukocytes into inflamed tissue, where they exert their specific tasks in host defense and immunosurveillance, or to sites of vascular inflammation, namely atherosclerotic lesions. It has been well documented that platelets not only bind to different subsets of leukocytes, enhancing their contact with endothelium, but can also secrete mediators, triggering leukocyte arrest and inducing transendothelial migration. However, it remains to be elucidated whether platelets react uniformly to activating stimuli or whether, dependent on the stimulus, show different mobilization and modulation of their surface receptors and release of mediators, resulting in the recruitment of specific leukocyte subtypes. Recent findings extend the role of platelets in immune-driven settings, as they appear to serve as an interface between innate and acquired host defense, recognizing microbial pathogens through TLRs, allowing engulfment of pathogens into their open canalicular system, or guiding and instructing lymphocytes toward specific sites and types of immune responses. The predictive value of platelet-derived secretory products should be meticulously scrutinized and validated in future prospective clinical trials.
|
Acknowledgments |
|---|
We thank Florian Schöbel for expert help with graphic design.
Sources of Funding
This work was supported by the Deutsche Forschungsgemeinschaft (WE1913/5).
Disclosures
None.
|
Footnotes |
|---|
Original received September 28, 2006; revision received November 2, 2006; accepted November 6, 2006.
|
References |
|---|
|
TopAbstractIntroductionSurface Molecules Linking...Soluble Immune MediatorsMicrobicidal ProteinsPlatelets Are Active Players...ConclusionsReferences |
|---|
1. Stenberg PE, McEver RP, Shuman MA, Jacques YV, Bainton DF. A platelet
-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol. 1985; 101: 880–886.2. Bonfanti R, Furie BC, Furie B, Wagner DD. PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells. Blood. 1989; 73: 1109–1112.
3. Li G, Sanders JM, Phan ET, Ley K, Sarembock IJ. Arterial macrophages and regenerating endothelial cells express P-selectin in atherosclerosis-prone apolipoprotein E-deficient mice. Am J Pathol. 2005; 167: 1511–1518.
4. Johnston GI, Cook RG, McEver RP. Cloning of GMP-140, a granule membrane protein of platelets and endothelium: sequence similarity to proteins involved in cell adhesion and inflammation. Cell. 1989; 56: 1033–1044.[CrossRef][Medline] [Order article via Infotrieve]
5. Frenette PS, Johnson RC, Hynes RO, Wagner DD. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci U S A. 1995; 92: 7450–7454.
6. Massberg S, Enders G, Leiderer R, Eisenmenger S, Vestweber D, Krombach F, Messmer K. Platelet-endothelial cell interactions during ischemia/reperfusion: the role of P-selectin. Blood. 1998; 92: 507–515.
7. Diacovo TG, Puri KD, Warnock RA, Springer TA, von Andrian UH. Platelet-mediated lymphocyte delivery to high endothelial venules. Science. 1996; 273: 252–255.[Abstract]
8. Larsen E, Celi A, Gilbert GE, Furie BC, Erban JK, Bonfanti R, Wagner DD, Furie B. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell. 1989; 59: 305–312.[CrossRef][Medline] [Order article via Infotrieve]
9. Diacovo TG, Roth SJ, Buccola JM, Bainton DF, Springer TA. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood. 1996; 88: 146–157.
10. Diacovo TG, Catalina MD, Siegelman MH, von Andrian UH. Circulating activated platelets reconstitute lymphocyte homing and immunity in L-selectin-deficient mice. J Exp Med. 1998; 187: 197–204.
11. da Costa Martins PA, van Gils JM, Mol A, Hordijk PL, Zwaginga JJ. Platelet binding to monocytes increases the adhesive properties of monocytes by up-regulating the expression and functionality of beta1 and beta2 integrins. J Leukoc Biol. 2006; 79: 499–507.
12. Yago T, Tsukuda M, Minami M. P-selectin binding promotes the adhesion of monocytes to VCAM-1 under flow conditions. J Immunol. 1999; 163: 367–373.
13. von Hundelshausen P, Weber KS, Huo Y, Proudfoot AE, Nelson PJ, Ley K, Weber C. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation. 2001; 103: 1772–1777.
14. Schober A, Manka D, von Hundelshausen P, Huo Y, Hanrath P, Sarembock IJ, Ley K, Weber C. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation. 2002; 106: 1523–1529.
15. Mause SF, von Hundelshausen P, Zernecke A, Koenen RR, Weber C. Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol. 2005; 25: 1512–1518.
16. Ma YQ, Plow EF, Geng JG. P-selectin binding to P-selectin glycoprotein ligand-1 induces an intermediate state of Mß2 activation and acts cooperatively with extracellular stimuli to support maximal adhesion of human neutrophils. Blood. 2004; 104: 2549–2556.
17. Atarashi K, Hirata T, Matsumoto M, Kanemitsu N, Miyasaka M. Rolling of Th1 cells via P-selectin glycoprotein ligand-1 stimulates LFA-1-mediated cell binding to ICAM-1. J Immunol. 2005; 174: 1424–1432.
18. Shattil SJ, Newman PJ. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood. 2004; 104: 1606–1615.
19. Bennett JS. Structure and function of the platelet integrin IIbß3. J Clin Invest. 2005; 115: 3363–3369.[CrossRef][Medline]
[Order article via Infotrieve]
20. Oki T, Kitaura J, Eto K, Lu Y, Maeda-Yamamoto M, Inagaki N, Nagai H, Yamanishi Y, Nakajima H, Kumagai H, Kitamura T. Integrin IIbß3 induces the adhesion and activation of mast cells through interaction with fibrinogen. J Immunol. 2006; 176: 52–60.
21. Bombeli T, Schwartz BR, Harlan JM. Adhesion of activated platelets to endothelial cells: evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), vß3 integrin, and GPIb. J Exp Med. 1998; 187: 329–339.
22. Buensuceso C, de Virgilio M, Shattil SJ. Detection of integrin IIbß3 clustering in living cells. J Biol Chem. 2003; 278: 15217–15224.
23. Loftus JC, Albrecht RM. Redistribution of the fibrinogen receptor of human platelets after surface activation. J Cell Biol. 1984; 99: 822–829.
24. Vinogradova O, Vaynberg J, Kong X, Haas TA, Plow EF, Qin J. Membrane-mediated structural transitions at the cytoplasmic face during integrin activation. Proc Natl Acad Sci U S A. 2004; 101: 4094–4099.
25. Vinogradova O, Velyvis A, Velyviene A, Hu B, Haas T, Plow E, Qin J. A structural mechanism of integrin IIbß3 "inside-out" activation as regulated by its cytoplasmic face. Cell. 2002; 110: 587–597.[CrossRef][Medline]
[Order article via Infotrieve]
26. Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, Wagner DD. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med. 2002; 8: 247–252.[CrossRef][Medline] [Order article via Infotrieve]
27. Prasad KS, Andre P, He M, Bao M, Manganello J, Phillips DR. Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci U S A. 2003; 100: 12367–12371.
28. Lincoff AM, Kereiakes DJ, Mascelli MA, Deckelbaum LI, Barnathan ES, Patel KK, Frederick B, Nakada MT, Topol EJ. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation. 2001; 104: 163–167.
29. Schneider DJ, Taatjes DJ, Sobel BE. Paradoxical inhibition of fibrinogen binding and potentiation of -granule release by specific types of inhibitors of glycoprotein IIb-IIIa. Cardiovasc Res. 2000; 45: 437–446.
30. Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation. 2003; 107: 1123–1128.
31. Welt FG, Rogers SD, Zhang X, Ehlers R, Chen Z, Nannizzi-Alaimo L, Phillips DR, Simon DI. GP IIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention. Catheter Cardiovasc Interv. 2004; 61: 185–189.[CrossRef][Medline] [Order article via Infotrieve]
32. Lederman S, Yellin MJ, Inghirami G, Lee JJ, Knowles DM, Chess L. Molecular interactions mediating T-B lymphocyte collaboration in human lymphoid follicles. Roles of T cell-B-cell-activating molecule (5c8 antigen) and CD40 in contact-dependent help. J Immunol. 1992; 149: 3817–3826.[Abstract]
33. Armitage RJ, Sato TA, Macduff BM, Clifford KN, Alpert AR, Smith CA, Fanslow WC. Identification of a source of biologically active CD40 ligand. Eur J Immunol. 1992; 22: 2071–2076.[Medline] [Order article via Infotrieve]
34. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998; 391: 591–594.[CrossRef][Medline] [Order article via Infotrieve]
35. Pignatelli P, Sanguigni V, Lenti L, Ferro D, Finocchi A, Rossi P, Violi F. gp91phox-dependent expression of platelet CD40 ligand. Circulation. 2004; 110: 1326–1329.
36. Lutgens E, Daemen MJ. CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med. 2002; 12: 27–32.[CrossRef][Medline] [Order article via Infotrieve]
37. Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res. 2003; 92: 1041–1048.
38. Danese S, de la Motte C, Reyes BM, Sans M, Levine AD, Fiocchi C. Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J Immunol. 2004; 172: 2011–2015.
39. Buchner K, Henn V, Grafe M, de Boer OJ, Becker AE, Kroczek RA. CD40 ligand is selectively expressed on CD4+ T cells and platelets: implications for CD40-CD40L signalling in atherosclerosis. J Pathol. 2003; 201: 288–295.[CrossRef][Medline] [Order article via Infotrieve]
40. Elzey BD, Tian J, Jensen RJ, Swanson AK, Lees JR, Lentz SR, Stein CS, Nieswandt B, Wang Y, Davidson BL, Ratliff TL. Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity. 2003; 19: 9–19.[CrossRef][Medline] [Order article via Infotrieve]
41. Elzey BD, Grant JF, Sinn HW, Nieswandt B, Waldschmidt TJ, Ratliff TL. Cooperation between platelet-derived CD154 and CD4+ T cells for enhanced germinal center formation. J Leukoc Biol. 2005; 78: 80–84.
42. Xu H, Zhang X, Mannon RB, Kirk AD. Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154. J Clin Invest. 2006; 116: 769–774.[CrossRef][Medline] [Order article via Infotrieve]
43. Lee SP, Ataga KI, Orringer EP, Phillips DR, Parise LV. Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol. 2006; 26: 1626–1631.[CrossRef][Medline] [Order article via Infotrieve]
44. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol. 2004; 22: 307–328.[CrossRef][Medline] [Order article via Infotrieve]
45. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood. 2001; 98: 1047–1054.
46. Chakrabarti S, Varghese S, Vitseva O, Tanriverdi K, Freedman JE. CD40 ligand influences platelet release of reactive oxygen intermediates. Arterioscler Thromb Vasc Biol. 2005; 25: 2428–2434.
47. Diacovo TG, deFougerolles AR, Bainton DF, Springer TA. A functional integrin ligand on the surface of platelets: intercellular adhesion molecule-2. J Clin Invest. 1994; 94: 1243–1251.[Medline] [Order article via Infotrieve]
48. Weber C, Springer TA. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to IIbß3 and stimulated by platelet-activating factor. J Clin Invest. 1997; 100: 2085–2093.[Medline]
[Order article via Infotrieve]
49. Kuijper PH, Gallardo Tores HI, Lammers JW, Sixma JJ, Koenderman L, Zwaginga JJ. Platelet associated fibrinogen and ICAM-2 induce firm adhesion of neutrophils under flow conditions. Thromb Haemost. 1998; 80: 443–448.[Medline] [Order article via Infotrieve]
50. Weber KS, Alon R, Klickstein LB. Sialylation of ICAM-2 on platelets impairs adhesion of leukocytes via LFA-1 and DC-SIGN. Inflammation. 2004; 28: 177–188.[CrossRef][Medline] [Order article via Infotrieve]
51. Naik UP, Ehrlich YH, Kornecki E. Mechanisms of platelet activation by a stimulatory antibody: cross-linking of a novel platelet receptor for monoclonal antibody F11 with the Fc gamma RII receptor. Biochem J. 1995; 310 (pt 1): 155–162.[Medline] [Order article via Infotrieve]
52. Sobocka MB, Sobocki T, Babinska A, Hartwig JH, Li M, Ehrlich YH, Kornecki E. Signaling pathways of the F11 receptor (F11R; a.k.a. JAM-1, JAM-A) in human platelets: F11R dimerization, phosphorylation and complex formation with the integrin GPIIIa. J Recept Signal Transduct Res. 2004; 24: 85–105.[CrossRef][Medline] [Order article via Infotrieve]
53. Martin-Padura I, Lostaglio S, Schneemann M, Williams L, Romano M, Fruscella P, Panzeri C, Stoppacciaro A, Ruco L, Villa A, Simmons D, Dejana E. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol. 1998; 142: 117–127.
54. Prota AE, Campbell JA, Schelling P, Forrest JC, Watson MJ, Peters TR, Aurrand-Lions M, Imhof BA, Dermody TS, Stehle T. Crystal structure of human junctional adhesion molecule 1: implications for reovirus binding. Proc Natl Acad Sci U S A. 2003; 100: 5366–5371.
55. Bazzoni G, Martinez-Estrada OM, Mueller F, Nelboeck P, Schmid G, Bartfai T, Dejana E, Brockhaus M. Homophilic interaction of junctional adhesion molecule. J Biol Chem. 2000; 275: 30970–30976.
56. Zernecke A, Liehn EA, Fraemohs L, von Hundelshausen P, Koenen RR, Corada M, Dejana E, Weber C. Importance of junctional adhesion molecule-A for neointimal lesion formation and infiltration in atherosclerosis-prone mice. Arterioscler Thromb Vasc Biol. 2006; 26: e10–e3.
57. Khandoga A, Kessler JS, Meissner H, Hanschen M, Corada M, Motoike T, Enders G, Dejana E, Krombach F. Junctional adhesion molecule-A deficiency increases hepatic ischemia-reperfusion injury despite reduction of neutrophil transendothelial migration. Blood. 2005; 106: 725–733.
58. Ostermann G, Weber KS, Zernecke A, Schroder A, Weber C. JAM-1 is a ligand of the beta(2) integrin LFA-1 involved in transendothelial migration of leukocytes. Nat Immunol. 2002; 3: 151–158.[CrossRef][Medline] [Order article via Infotrieve]
59. Santoso S, Sachs UJ, Kroll H, Linder M, Ruf A, Preissner KT, Chavakis T. The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J Exp Med. 2002; 196: 679–691.
60. Simon DI, Chen Z, Xu H, Li CQ, Dong J, McIntire LV, Ballantyne CM, Zhang L, Furman MI, Berndt MC, Lopez JA. Platelet glycoprotein Ib is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med. 2000; 192: 193–204.
61. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006; 124: 783–801.[CrossRef][Medline] [Order article via Infotrieve]
62. Shiraki R, Inoue N, Kawasaki S, Takei A, Kadotani M, Ohnishi Y, Ejiri J, Kobayashi S, Hirata K, Kawashima S, Yokoyama M. Expression of Toll-like receptors on human platelets. Thromb Res. 2004; 113: 379–385.[CrossRef][Medline] [Order article via Infotrieve]
63. Andonegui G, Kerfoot SM, McNagny K, Ebbert KV, Patel KD, Kubes P. Platelets express functional Toll-like receptor-4. Blood. 2005; 106: 2417–2423.
64. Ward JR, Bingle L, Judge HM, Brown SB, Storey RF, Whyte MK, Dower SK, Buttle DJ, Sabroe I. Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor. Thromb Haemost. 2005; 94: 831–838.[Medline] [Order article via Infotrieve]
65. Aslam R, Speck ER, Kim M, Crow AR, Bang KW, Nestel FP, Ni H, Lazarus AH, Freedman J, Semple JW. Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor- production in vivo. Blood. 2006; 107: 637–641.
66. Stahl AL, Svensson M, Morgelin M, Svanborg C, Tarr PI, Mooney JC, Watkins SL, Johnson R, Karpman D. Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets via TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome. Blood. 2006; 108: 167–176.
67. Damas JK, Jensenius M, Ueland T, Otterdal K, Yndestad A, Froland SS, Rolain JM, Myrvang B, Raoult D, Aukrust P. Increased levels of soluble CD40L in African tick bite fever: possible involvement of TLRs in the pathogenic interaction between Rickettsia africae, endothelial cells, and platelets. J Immunol. 2006; 177: 2699–2706.
68. Horuk R. Molecular properties of the chemokine receptor family. Trends Pharmacol Sci. 1994; 15: 159–165.[CrossRef][Medline] [Order article via Infotrieve]
69. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol. 2004; 22: 891–928.[CrossRef][Medline] [Order article via Infotrieve]
70. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev. 2000; 52: 145–176.
71. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, Kitamura Y, Matsushima K, Yoshida N, Nishikawa S, Kishimoto T, Nagasawa T. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature. 1998; 393: 591–594.[CrossRef][Medline] [Order article via Infotrieve]
72. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 1998; 393: 595–599.[CrossRef][Medline] [Order article via Infotrieve]
73. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, Yoshida N, Kikutani H, Kishimoto T. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 1996; 382: 635–638.[CrossRef][Medline] [Order article via Infotrieve]
74. Wang JF, Liu ZY, Groopman JE. The -chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulates migration and adhesion. Blood. 1998; 92: 756–764.
75. Kowalska MA, Ratajczak J, Hoxie J, Brass LF, Gewirtz A, Poncz M, Ratajczak MZ. Megakaryocyte precursors, megakaryocytes and platelets express the HIV coreceptor CXCR4 on their surface: determination of response to stromal-derived factor-1 by megakaryocytes and platelets. Br J Haematol. 1999; 104: 220–229.[CrossRef][Medline] [Order article via Infotrieve]
76. Hamada T, Mohle R, Hesselgesser J, Hoxie J, Nachman RL, Moore MA, Rafii S. Transendothelial migration of megakaryocytes in response to stromal cell-derived factor 1 (SDF-1) enhances platelet formation. J Exp Med. 1998; 188: 539–548.
77. Riviere C, Subra F, Cohen-Solal K, Cordette-Lagarde V, Letestu R, Auclair C, Vainchenker W, Louache F. Phenotypic and functional evidence for the expression of CXCR4 receptor during megakaryocytopoiesis. Blood. 1999; 93: 1511–1523.
78. Kowalska MA, Ratajczak MZ, Majka M, Jin J, Kunapuli S, Brass L, Poncz M. Stromal cell-derived factor-1 and macrophage-derived chemokine: 2 chemokines that activate platelets. Blood. 2000; 96: 50–57.
79. D’Apuzzo M, Rolink A, Loetscher M, Hoxie JA, Clark-Lewis I, Melchers F, Baggiolini M, Moser B. The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4. Eur J Immunol. 1997; 27: 1788–1793.[Medline] [Order article via Infotrieve]
80. Berthebaud M, Riviere C, Jarrier P, Foudi A, Zhang Y, Compagno D, Galy A, Vainchenker W, Louache F. RGS16 is a negative regulator of SDF-1-CXCR4 signaling in megakaryocytes. Blood. 2005; 106: 2962–2968.
81. Gear AR, Suttitanamongkol S, Viisoreanu D, Polanowska-Grabowska RK, Raha S, Camerini D. Adenosine diphosphate strongly potentiates the ability of the chemokines MDC, TARC, and SDF-1 to stimulate platelet function. Blood. 2001; 97: 937–945.
82. Majka M, Ratajczak J, Baj-Krzyworzek M, Kijowski J, Reca R, Machalinski B, Kubicze K, Ratajczak MZ. Biological significance of chemokine receptor expression by normal human megakaryoblasts. Folia Histochem Cytobiol. 2001; 39: 235–244.[Medline] [Order article via Infotrieve]
83. Abi-Younes S, Sauty A, Mach F, Sukhova GK, Libby P, Luster AD. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res. 2000; 86: 131–138.
84. Massberg S, Konrad I, Schurzinger K, Lorenz M, Schneider S, Zohlnhoefer D, Hoppe K, Schiemann M, Kennerknecht E, Sauer S, Schulz C, Kerstan S, Rudelius M, Seidl S, Sorge F, Langer H, Peluso M, Goyal P, Vestweber D, Emambokus NR, Busch DH, Frampton J, Gawaz M. Platelets secrete stromal cell-derived factor 1 and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. J Exp Med. 2006.
85. Zernecke A, Schober A, Bot I, von Hundelshausen P, Liehn EA, Mopps B, Mericskay M, Gierschik P, Biessen EA, Weber C. SDF-1/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. Circ Res. 2005; 96: 784–791.
86. Clemetson KJ, Clemetson JM, Proudfoot AE, Power CA, Baggiolini M, Wells TN. Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. Blood. 2000; 96: 4046–4054.
87. Abi-Younes S, Si-Tahar M, Luster AD. The CC chemokines MDC and TARC induce platelet activation via CCR4. Thromb Res. 2001; 101: 279–289.[CrossRef][Medline] [Order article via Infotrieve]
88. Suttitanamongkol S, Gear AR. ADP receptor antagonists inhibit platelet aggregation induced by the chemokines SDF-1, MDC and TARC. FEBS Lett. 2001; 490: 84–87.[CrossRef][Medline] [Order article via Infotrieve]
89. Schafer A, Schulz C, Eigenthaler M, Fraccarollo D, Kobsar A, Gawaz M, Ertl G, Walter U, Bauersachs J. Novel role of the membrane-bound chemokine fractalkine in platelet activation and adhesion. Blood. 2004; 103: 407–412.
90. Umehara H, Bloom E, Okazaki T, Domae N, Imai T. Fractalkine and vascular injury. Trends Immunol. 2001; 22: 602–607.[CrossRef][Medline] [Order article via Infotrieve]
91. Greaves DR, Hakkinen T, Lucas AD, Liddiard K, Jones E, Quinn CM, Senaratne J, Green FR, Tyson K, Boyle J, Shanahan C, Weissberg PL, Gordon S, Yla-Hertualla S. Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2001; 21: 923–929.
92. Combadiere C, Potteaux S, Gao JL, Esposito B, Casanova S, Lee EJ, Debre P, Tedgui A, Murphy PM, Mallat Z. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation. 2003; 107: 1009–1016.
93. Lesnik P, Haskell CA, Charo IF. Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest. 2003; 111: 333–340.[CrossRef][Medline] [Order article via Infotrieve]
94. Brandt E, Ludwig A, Petersen F, Flad HD. Platelet-derived CXC chemokines: old players in new games. Immunol Rev. 2000; 177: 204–216.[CrossRef][Medline] [Order article via Infotrieve]
95. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest. 1989; 84: 1045–1049.[Medline] [Order article via Infotrieve]
96. Pan Y, Lloyd C, Zhou H, Dolich S, Deeds J, Gonzalo JA, Vath J, Gosselin M, Ma J, Dussault B, Woolf E, Alperin G, Culpepper J, Gutierrez-Ramos JC, Gearing D. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature. 1997; 387: 611–617.[CrossRef][Medline] [Order article via Infotrieve]
97. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997; 385: 640–644.[CrossRef][Medline] [Order article via Infotrieve]
98. Kennedy J, Kelner GS, Kleyensteuber S, Schall TJ, Weiss MC, Yssel H, Schneider PV, Cocks BG, Bacon KB, Zlotnik A. Molecular cloning and functional characterization of human lymphotactin. J Immunol. 1995; 155: 203–209.[Abstract]
99. Power CA, Furness RB, Brawand C, Wells TN. Cloning of a full-length cDNA encoding the neutrophil-activating peptide ENA-78 from human platelets. Gene. 1994; 151: 333–334.[CrossRef][Medline] [Order article via Infotrieve]
100. Yan Z, Zhang J, Holt JC, Stewart GJ, Niewiarowski S, Poncz M. Structural requirements of platelet chemokines for neutrophil activation. Blood. 1994; 84: 2329–2339.
101. Clark-Lewis I, Schumacher C, Baggiolini M, Moser B. Structure-activity relationships of interleukin-8 determined using chemically synthesized analogs. Critical role of NH2-terminal residues and evidence for uncoupling of neutrophil chemotaxis, exocytosis, and receptor binding activities. J Biol Chem. 1991; 266: 23128–23134.
102. Petersen F, Bock L, Flad HD, Brandt E. A chondroitin sulfate proteoglycan on human neutrophils specifically binds platelet factor 4 and is involved in cell activation. J Immunol. 1998; 161: 4347–4355.
103. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, Marra F, Romagnani S, Serio M, Romagnani P. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med. 2003; 197: 1537–1549.
104. Kasper B, Brandt E, Bulfone-Paus S, Petersen F. Platelet factor 4 (PF-4)-induced neutrophil adhesion is controlled by src-kinases while PF-4-mediated exocytosis requires the additional activation of p38 MAP kinase and phosphatidylinositol 3-kinase. Blood. 2004; 103: 1602–1610.
105. Petersen F, Ludwig A, Flad HD, Brandt E. TNF- renders human neutrophils responsive to platelet factor 4. Comparison of PF-4 and IL-8 reveals different activity profiles of the two chemokines. J Immunol. 1996; 156: 1954–1962.[Abstract]
106. Gentilini G, Kirschbaum NE, Augustine JA, Aster RH, Visentin GP. Inhibition of human umbilical vein endothelial cell proliferation by the CXC chemokine, platelet factor 4 (PF4), is associated with impaired downregulation of p21(Cip1/WAF1). Blood. 1999; 93: 25–33.
107. Broxmeyer HE, Sherry B, Cooper S, Lu L, Maze R, Beckmann MP, Cerami A, Ralph P. Comparative analysis of the human macrophage inflammatory protein family of cytokines (chemokines) on proliferation of human myeloid progenitor cells. Interacting effects involving suppression, synergistic suppression, and blocking of suppression. J Immunol. 1993; 150: 3448–3458.[Abstract]
108. Nesmelova IV, Sham Y, Dudek AZ, van Eijk LI, Wu G, Slungaard A, Mortari F, Griffioen AW, Mayo KH. Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural level. J Biol Chem. 2005; 280: 4948–4958.
109. Dudek AZ, Nesmelova I, Mayo K, Verfaillie CM, Pitchford S, Slungaard A. Platelet factor 4 promotes adhesion of hematopoietic progenitor cells and binds IL-8: novel mechanisms for modulation of hematopoiesis. Blood. 2003; 101: 4687–4694.
110. Chadderton NS, Stringer SE. Interaction of platelet factor 4 with fibroblast growth factor 2 is stabilised by heparan sulphate. Int J Biochem Cell Biol. 2003; 35: 1052–1055.[CrossRef][Medline] [Order article via Infotrieve]
111. von Hundelshausen P, Koenen RR, Sack M, Mause SF, Adriaens W, Proudfoot AE, Hackeng TM, Weber C. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood. 2005; 105: 924–930.
112. Perollet C, Han ZC, Savona C, Caen JP, Bikfalvi A. Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood. 1998; 91: 3289–3299.
113. Slungaard A. Platelet factor 4 modulation of the thrombomodulin-protein C system. Crit Care Med. 2004; 32: S331–S335.[CrossRef][Medline] [Order article via Infotrieve]
114. Gengrinovitch S, Greenberg SM, Cohen T, Gitay-Goren H, Rockwell P, Maione TE, Levi BZ, Neufeld G. Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms. J Biol Chem. 1995; 270: 15059–15065.
115. Weber C, Koenen RR. Fine-tuning leukocyte responses: towards a chemokine ‘interactome’. Trends Immunol. 2006; 27: 268–273.[CrossRef][Medline] [Order article via Infotrieve]
116. Schall TJ, Jongstra J, Dyer BJ, Jorgensen J, Clayberger C, Davis MM, Krensky AM. A human T cell-specific molecule is a member of a new gene family. J Immunol. 1988; 141: 1018–1025.[Abstract]
117. Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature. 1990; 347: 669–671.[CrossRef][Medline] [Order article via Infotrieve]
118. Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schroder JM. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med. 1992; 176: 587–592.
119. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, Ley K. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med. 2003; 9: 61–67.[CrossRef][Medline] [Order article via Infotrieve]
120. Veillard NR, Kwak B, Pelli G, Mulhaupt F, James RW, Proudfoot AE, Mach F. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res. 2004; 94: 253–261.
121. Fujisawa T, Fujisawa R, Kato Y, Nakayama T, Morita A, Katsumata H, Nishimori H, Iguchi K, Kamiya H, Gray PW, Chantry D, Suzuki R, Yoshie O. Presence of high contents of thymus and activation-regulated chemokine in platelets and elevated plasma levels of thymus and activation-regulated chemokine and macrophage-derived chemokine in patients with atopic dermatitis. J Allergy Clin Immunol. 2002; 110: 139–146.[CrossRef][Medline] [Order article via Infotrieve]
122. Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res. 2005; 96: 612–616.
123. Stevenson FT, Torrano F, Locksley RM, Lovett DH. Interleukin 1: the patterns of translation and intracellular distribution support alternative secretory mechanisms. J Cell Physiol. 1992; 152: 223–231.[CrossRef][Medline] [Order article via Infotrieve]
124. Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem. 1991; 266: 10331–10336.
125. Schreuder H, Tardif C, Trump-Kallmeyer S, Soffientini A, Sarubbi E, Akeson A, Bowlin T, Yanofsky S, Barrett RW. A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature. 1997; 386: 194–200.[CrossRef][Medline] [Order article via Infotrieve]
126. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996; 87: 2095–2147.
127. Gabay C. Cytokine inhibitors in the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2002; 2: 135–149.[CrossRef][Medline] [Order article via Infotrieve]
128. Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 2002; 13: 323–340.[CrossRef][Medline] [Order article via Infotrieve]
129. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol. 1998; 16: 27–55.[CrossRef][Medline] [Order article via Infotrieve]
130. Brody JI, Pickering NJ, Capuzzi DM, Fink GB, Can CA, Gomez F. Interleukin-1 as a factor in occlusive vascular disease. Am J Clin Pathol. 1992; 97: 8–13.[Medline]
[Order article via Infotrieve]
131. Merhi-Soussi F, Kwak BR, Magne D, Chadjichristos C, Berti M, Pelli G, James RW, Mach F, Gabay C. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res. 2005; 66: 583–593.
132. Ku G, Thomas CE, Akeson AL, Jackson RL. Induction of interleukin 1 beta expression from human peripheral blood monocyte-derived macrophages by 9-hydroxyoctadecadienoic acid. J Biol Chem. 1992; 267: 14183–14188.
133. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999; 340: 115–126.
134. Hawrylowicz CM, Santoro SA, Platt FM, Unanue ER. Activated platelets express IL-1 activity. J Immunol. 1989; 143: 4015–4018.[Abstract]
135. Hawrylowicz CM, Howells GL, Feldmann M. Platelet-derived interleukin 1 induces human endothelial adhesion molecule expression and cytokine production. J Exp Med. 1991; 174: 785–790.
136. Kaplanski G, Porat R, Aiura K, Erban JK, Gelfand JA, Dinarello CA. Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1-mediated event. Blood. 1993; 81: 2492–2495.
137. Gawaz M, Brand K, Dickfeld T, Pogatsa-Murray G, Page S, Bogner C, Koch W, Schomig A, Neumann F. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis. Atherosclerosis. 2000; 148: 75–85.[CrossRef][Medline] [Order article via Infotrieve]
138. Lindemann S, Tolley ND, Eyre JR, Kraiss LW, Mahoney TM, Weyrich AS. Integrins regulate the intracellular distribution of eukaryotic initiation factor 4E in platelets. A checkpoint for translational control. J Biol Chem. 2001; 276: 33947–33951.
139. Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA, Weyrich AS. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol. 2001; 154: 485–490.
140. Denis MM, Tolley ND, Bunting M, Schwertz H, Jiang H, Lindemann S, Yost CC, Rubner FJ, Albertine KH, Swoboda KJ, Fratto CM, Tolley E, Kraiss LW, McIntyre TM, Zimmerman GA, Weyrich AS. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell. 2005; 122: 379–391.[CrossRef][Medline] [Order article via Infotrieve]
141. Lehrer RI, Lichtenstein AK, Ganz T. Defensins: antimicrobial and cytotoxic peptides of mammalian cells. Annu Rev Immunol. 1993; 11: 105–128.[CrossRef][Medline] [Order article via Infotrieve]
142. Ganz T, Selsted ME, Szklarek D, Harwig SS, Daher K, Bainton DF, Lehrer RI. Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest. 1985; 76: 1427–1435.[Medline] [Order article via Infotrieve]
143. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell. 1997; 88: 553–560.[CrossRef][Medline] [Order article via Infotrieve]
144. Schroder JM. Epithelial peptide antibiotics. Biochem Pharmacol. 1999; 57: 121–134.[CrossRef][Medline] [Order article via Infotrieve]
145. Yeaman MR, Puentes SM, Norman DC, Bayer AS. Partial characterization and staphylocidal activity of thrombin-induced platelet microbicidal protein. Infect Immun. 1992; 60: 1202–1209.
146. Dankert J, van der Werff J, Zaat SA, Joldersma W, Klein D, Hess J. Involvement of bactericidal factors from thrombin-stimulated platelets in clearance of adherent viridans streptococci in experimental infective endocarditis. Infect Immun. 1995; 63: 663–671.[Abstract]
147. Weksler BB, Nachman RL. Rabbit platelet bactericidal protein. J Exp Med. 1971; 134: 1114–1130.[Abstract]
148. Zaat SA, Koper M, Grasselier H, Meeldijk J, Krijgsveld J, Dankert J. Cell-adherent glucan does not protect endocarditis-causing viridans streptococci against bactericidal proteins from human blood platelets. Adv Exp Med Biol. 1997; 418: 709–712.[Medline] [Order article via Infotrieve]
149. Yeaman MR, Norman DC, Bayer AS. Staphylococcus aureus susceptibility to thrombin-induced platelet microbicidal protein is independent of platelet adherence and aggregation in vitro. Infect Immun. 1992; 60: 2368–2374.
150. Krijgsveld J, Zaat SA, Meeldijk J, van Veelen PA, Fang G, Poolman B, Brandt E, Ehlert JE, Kuijpers AJ, Engbers GH, Feijen J, Dankert J. Thrombocidins, microbicidal proteins from human blood platelets, are C-terminal deletion products of CXC chemokines. J Biol Chem. 2000; 275: 20374–20381.
151. Yang D, Chen Q, Hoover DM, Staley P, Tucker KD, Lubkowski J, Oppenheim JJ. Many chemokines including CCL20/MIP-3 display antimicrobial activity. J Leukoc Biol. 2003; 74: 448–455.
152. Yount NY, Gank KD, Xiong YQ, Bayer AS, Pender T, Welch WH, Yeaman MR. Platelet microbicidal protein 1: structural themes of a multifunctional antimicrobial peptide. Antimicrob Agents Chemother. 2004; 48: 4395–4404.
153. Cole AM, Ganz T, Liese AM, Burdick MD, Liu L, Strieter RM. Cutting edge: IFN-inducible ELR- CXC chemokines display defensin-like antimicrobial activity. J Immunol. 2001; 167: 623–627.
154. Bjorstad A, Fu H, Karlsson A, Dahlgren C, Bylund J. Interleukin-8-derived peptide has antibacterial activity. Antimicrob Agents Chemother. 2005; 49: 3889–3895.
155. Hancock RE. Peptide antibiotics. Lancet. 1997; 349: 418–422.[CrossRef][Medline] [Order article via Infotrieve]
156. Yeaman MR, Bayer AS. Antimicrobial peptides from platelets. Drug Resist Updat. 1999; 2: 116–126.[CrossRef][Medline] [Order article via Infotrieve]
157. Fitzgerald JR, Foster TJ, Cox D. The interaction of bacterial pathogens with platelets. Nat Rev Microbiol. 2006; 4: 445–457.[CrossRef][Medline] [Order article via Infotrieve]
158. Erickson PR, Herzberg MC, Tierney G. Cross-reactive immunodeterminants on Streptococcus sanguis and collagen. Predicting a structural motif of platelet-interactive domains. J Biol Chem. 1992; 267: 10018–10023.
159. Scheld WM, Valone JA, Sande MA. Bacterial adherence in the pathogenesis of endocarditis. Interaction of bacterial dextran, platelets, and fibrin. J Clin Invest. 1978; 61: 1394–1404.[Medline] [Order article via Infotrieve]
160. Schwarz-Linek U, Werner JM, Pickford AR, Gurusiddappa S, Kim JH, Pilka ES, Briggs JA, Gough TS, Hook M, Campbell ID, Potts JR. Pathogenic bacteria attach to human fibronectin through a tandem beta-zipper. Nature. 2003; 423: 177–181.[CrossRef][Medline] [Order article via Infotrieve]
161. Boden MK, Flock JI. Fibrinogen-binding protein/clumping factor from Staphylococcus aureus. Infect Immun. 1989; 57: 2358–2363.
162. Erickson PR, Herzberg MC. The Streptococcus sanguis platelet aggregation-associated protein. Identification and characterization of the minimal platelet-interactive domain. J Biol Chem. 1993; 268: 1646–1649.
163. Loughman A, Fitzgerald JR, Brennan MP, Higgins J, Downer R, Cox D, Foster TJ. Roles for fibrinogen, immunoglobulin and complement in platelet activation promoted by Staphylococcus aureus clumping factor A. Mol Microbiol. 2005; 57: 804–818.[CrossRef][Medline] [Order article via Infotrieve]
164. Fitzgerald JR, Loughman A, Keane F, Brennan M, Knobel M, Higgins J, Visai L, Speziale P, Cox D, Foster TJ. Fibronectin-binding proteins of Staphylococcus aureus mediate activation of human platelets via fibrinogen and fibronectin bridges to integrin GPIIb/IIIa and IgG binding to the FcgammaRIIa receptor. Mol Microbiol. 2006; 59: 212–230.[CrossRef][Medline] [Order article via Infotrieve]
165. Durack DT. Experimental bacterial endocarditis. IV. Structure and evolution of very early lesions. J Pathol. 1975; 115: 81–89.[CrossRef][Medline] [Order article via Infotrieve]
166. Sullam PM, Bayer AS, Foss WM, Cheung AL. Diminished platelet binding in vitro by Staphylococcus aureus is associated with reduced virulence in a rabbit model of infective endocarditis. Infect Immun. 1996; 64: 4915–4921.[Abstract]
167. Dhawan VK, Yeaman MR, Cheung AL, Kim E, Sullam PM, Bayer AS. Phenotypic resistance to thrombin-induced platelet microbicidal protein in vitro is correlated with enhanced virulence in experimental endocarditis due to Staphylococcus aureus. Infect Immun. 1997; 65: 3293–3299.[Abstract]
168. Mercier RC, Rybak MJ, Bayer AS, Yeaman MR. Influence of platelets and platelet microbicidal protein susceptibility on the fate of Staphylococcus aureus in an in vitro model of infective endocarditis. Infect Immun. 2000; 68: 4699–4705.
169. Kupferwasser LI, Yeaman MR, Shapiro SM, Nast CC, Bayer AS. In vitro susceptibility to thrombin-induced platelet microbicidal protein is associated with reduced disease progression and complication rates in experimental Staphylococcus aureus endocarditis: microbiological, histopathologic, and echocardiographic analyses. Circulation. 2002; 105: 746–752.
170. Youssefian T, Drouin A, Masse JM, Guichard J, Cramer EM. Host defense role of platelets: engulfment of HIV and Staphylococcus aureus occurs in a specific subcellular compartment and is enhanced by platelet activation. Blood. 2002; 99: 4021–4029.
171. Pawar P, Shin PK, Mousa SA, Ross JM, Konstantopoulos K. Fluid shear regulates the kinetics and receptor specificity of Staphylococcus aureus binding to activated platelets. J Immunol. 2004; 173: 1258–1265.
172. White JG. Platelets are covercytes, not phagocytes: uptake of bacteria involves channels of the open canalicular system. Platelets. 2005; 16: 121–131.[CrossRef][Medline] [Order article via Infotrieve]
173. White JG. Why human platelets fail to kill bacteria. Platelets. 2006; 17: 191–200.[CrossRef][Medline] [Order article via Infotrieve]
174. Zucker-Franklin D, Seremetis S, Zheng ZY. Internalization of human immunodeficiency virus type I and other retroviruses by megakaryocytes and platelets. Blood. 1990; 75: 1920–1923.
175. Boukour S, Masse JM, Benit L, Dubart-Kupperschmitt A, Cramer EM. Lentivirus degradation and DC-SIGN expression by human platelets and megakaryocytes. J Thromb Haemost. 2006; 4: 426–435.[CrossRef][Medline] [Order article via Infotrieve]
176. Chaipan C, Soilleux EJ, Simpson P, Hofmann H, Gramberg T, Marzi A, Geier M, Stewart EA, Eisemann J, Steinkasserer A, Suzuki-Inoue K, Fuller GL, Pearce AC, Watson SP, Hoxie JA, Baribaud F, Pohlmann S. DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets. J Virol. 2006; 80: 8951–8960.
177. Johnson RC, Chapman SM, Dong ZM, Ordovas JM, Mayadas TN, Herz J, Hynes RO, Schaefer EJ, Wagner DD. Absence of P-selectin delays fatty streak formation in mice. J Clin Invest. 1997; 99: 1037–1043.[Medline] [Order article via Infotrieve]
178. Collins RG, Velji R, Guevara NV, Hicks MJ, Chan L, Beaudet AL. P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J Exp Med. 2000; 191: 189–194.
179. Dong ZM, Brown AA, Wagner DD. Prominent role of P-selectin in the development of advanced atherosclerosis in ApoE-deficient mice. Circulation. 2000; 101: 2290–2295.
180. Burger PC, Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion development. Blood. 2003; 101: 2661–2666.
181. Theilmeier G, Lenaerts T, Remacle C, Collen D, Vermylen J, Hoylaerts MF. Circulating activated platelets assist THP-1 monocytoid/endothelial cell interaction under shear stress. Blood. 1999; 94: 2725–2734.
182. Phillips JW, Barringhaus KG, Sanders JM, Hesselbacher SE, Czarnik AC, Manka D, Vestweber D, Ley K, Sarembock IJ. Single injection of P-selectin or P-selectin glycoprotein ligand-1 monoclonal antibody blocks neointima formation after arterial injury in apolipoprotein E-deficient mice. Circulation. 2003; 107: 2244–2249.
183. Chi H, Messas E, Levine RA, Graves DT, Amar S. Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications. Circulation. 2004; 110: 1678–1685.
184. Chuluyan HE, Schall TJ, Yoshimura T, Issekutz AC. IL-1 activation of endothelium supports VLA-4 (CD49d/CD29)-mediated monocyte transendothelial migration to C5a, MIP-1, RANTES, and PAF but inhibits migration to MCP-1: a regulatory role for endothelium-derived MCP-1. J Leukoc Biol. 1995; 58: 71–79.[Abstract]
185. Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y, Asano M, Moriwaki H, Seishima M. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2003; 23: 656–660.
186. Massberg S, Brand K, Gruner S, Page S, Muller E, Muller I, Bergmeier W, Richter T, Lorenz M, Konrad I, Nieswandt B, Gawaz M. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med. 2002; 196: 887–896.
187. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998; 394: 200–203.[CrossRef][Medline] [Order article via Infotrieve]
188. Schonbeck U, Sukhova GK, Shimizu K, Mach F, Libby P. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci U S A. 2000; 97: 7458–7463.
189. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML. CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003; 348: 1104–1111.
190. de Lemos JA, Zirlik A, Schonbeck U, Varo N, Murphy SA, Khera A, McGuire DK, Stanek G, Lo HS, Nuzzo R, Morrow DA, Peshock R, Libby P. Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol. 2005; 25: 2192–2196.
191. Zernecke A, Bidzhekov K, Ozuyaman B, Fraemohs L, Liehn EA, Luscher-Firzlaff JM, Luscher B, Schrader J, Weber C. CD73/ecto-5'-nucleotidase protects against vascular inflammation and neointima formation. Circulation. 2006; 113: 2120–2127.
192. Tiedt R, Schomber T, Hao-Shen H, Skoda RC. Pf4-Cre transgenic mice allow generating lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. Blood. In press.
193. Simeoni E, Winkelmann BR, Hoffmann MM, Fleury S, Ruiz J, Kappenberger L, Marz W, Vassalli G. Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur Heart J. 2004; 25: 1438–1446.
194. Pitsilos S, Hunt J, Mohler ER, Prabhakar AM, Poncz M, Dawicki J, Khalapyan TZ, Wolfe ML, Fairman R, Mitchell M, Carpenter J, Golden MA, Cines DB, Sachais BS. Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters. Thromb Haemost. 2003; 90: 1112–1120.[Medline] [Order article via Infotrieve]
195. Gewirtz AM, Zhang J, Ratajczak J, Ratajczak M, Park KS, Li C, Yan Z, Poncz M. Chemokine regulation of human megakaryocytopoiesis. Blood. 1995; 86: 2559–2567.
196. Capitanio AM, Niewiarowski S, Rucinski B, Tuszynski GP, Cierniewski CS, Hershock D, Kornecki E. Interaction of platelet factor 4 with human platelets. Biochim Biophys Acta. 1985; 839: 161–173.[Medline] [Order article via Infotrieve]
197. Boehlen F, Clemetson KJ. Platelet chemokines and their receptors: what is their relevance to platelet storage and transfusion practice? Transfus Med. 2001; 11: 403–417.[CrossRef][Medline] [Order article via Infotrieve]
198. Struyf S, Burdick MD, Proost P, Van Damme J, Strieter RM. Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ Res. 2004; 95: 855–857.
199. Klinger MH. Platelets and inflammation. Anat Embryol (Berl). 1997; 196: 1–11.[CrossRef][Medline] [Order article via Infotrieve]
200. Gear AR, Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation. 2003; 10: 335–350.[CrossRef][Medline] [Order article via Infotrieve]
201. Power CA, Clemetson JM, Clemetson KJ, Wells TN. Chemokine and chemokine receptor mRNA expression in human platelets. Cytokine. 1995; 7: 479–482.[CrossRef][Medline] [Order article via Infotrieve]
202. Schober A, Zernecke A, Liehn EA, von Hundelshausen P, Knarren S, Kuziel WA, Weber C. Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets. Circ Res. 2004; 95: 1125–1133.
203. Klinger MH, Wilhelm D, Bubel S, Sticherling M, Schroder JM, Kuhnel W. Immunocytochemical localization of the chemokines RANTES and MIP-1 within human platelets and their release during storage. Int Arch Allergy Immunol. 1995; 107: 541–546.[Medline]
[Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  J. G. Filep Platelets Affect the Structure and Function of C-Reactive Protein Circ. Res., July 17, 2009; 105(2): 109 - 111. [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Chen, D. Hou, L. Pendyala, J. A. Goudevenos, and N. G. Kounis Drug-Eluting Stent Thrombosis: The Kounis Hypersensitivity-Associated Acute Coronary Syndrome Revisited J. Am. Coll. Cardiol. Intv., July 1, 2009; 2(7): 583 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Blasco-Colmenares, T. M. Perl, E. Guallar, W. A. Baumgartner, J. V. Conte, D. Alejo, R. Pastor-Barriuso, A. R. Sharrett, and N. Faraday Aspirin Plus Clopidogrel and Risk of Infection After Coronary Artery Bypass Surgery Arch Intern Med, April 27, 2009; 169(8): 788 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Blair, S. Rex, O. Vitseva, L. Beaulieu, K. Tanriverdi, S. Chakrabarti, C. Hayashi, C. A. Genco, M. Iafrati, and J. E. Freedman Stimulation of Toll-Like Receptor 2 in Human Platelets Induces a Thromboinflammatory Response Through Activation of Phosphoinositide 3-Kinase Circ. Res., February 13, 2009; 104(3): 346 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Sun, X. Wang, J. L. Degen, and D. Ginsburg Reduced thrombin generation increases host susceptibility to group A streptococcal infection Blood, February 5, 2009; 113(6): 1358 - 1364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P. Smirnova, A. A. Ptitsyn, K. J. Austin, H. Bielefeldt-Ohmann, H. Van Campen, H. Han, A. L. van Olphen, and T. R. Hansen Persistent fetal infection with bovine viral diarrhea virus differentially affects maternal blood cell signal transduction pathways Physiol Genomics, February 2, 2009; 36(3): 129 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. van Gils, J. J. Zwaginga, and P. L. Hordijk Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases J. Leukoc. Biol., February 1, 2009; 85(2): 195 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Qian, F. Xie, A. W. Gibson, J. C. Edberg, R. P. Kimberly, and J. Wu Functional expression of IgA receptor Fc{alpha}RI on human platelets J. Leukoc. Biol., December 1, 2008; 84(6): 1492 - 1500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zernecke, E. Shagdarsuren, and C. Weber Chemokines in Atherosclerosis: An Update Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1897 - 1908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Aukrust, B. Halvorsen, A. Yndestad, T. Ueland, E. Oie, K. Otterdal, L. Gullestad, and J. K. Damas Chemokines and Cardiovascular Risk Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1909 - 1919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Gleissner, P. von Hundelshausen, and K. Ley Platelet Chemokines in Vascular Disease Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1920 - 1927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sood, L. Sholl, B. Isermann, M. Zogg, S. R. Coughlin, and H. Weiler Maternal Par4 and platelets contribute to defective placenta formation in mouse embryos lacking thrombomodulin Blood, August 1, 2008; 112(3): 585 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Li Platelet-lymphocyte cross-talk J. Leukoc. Biol., May 1, 2008; 83(5): 1069 - 1078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Zimmerman and A. S. Weyrich Signal-Dependent Protein Synthesis by Activated Platelets: New Pathways to Altered Phenotype and Function Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): s17 - s24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Duygu, V. Barisik, H. Kurt, U. Turk, E. Ercan, and S. Kose Prognostic value of plasma soluble CD40 ligand in patients with chronic non-valvular atrial fibrillation Europace, February 1, 2008; 10(2): 210 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N.-K. Hsieh and H. I. Chen Interacting Leukocytes Predict Atherosclerosis and Restenosis Stroke, December 1, 2007; 38(12): e162 - e163. [Full Text] [PDF]
|
|
|
|
|
|
E. Galkina and K. Ley Vascular Adhesion Molecules in Atherosclerosis Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2292 - 2301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Semple, R. Aslam, M. Kim, E. R. Speck, and J. Freedman Platelet-bound lipopolysaccharide enhances Fc receptor mediated phagocytosis of IgG-opsonized platelets Blood, June 1, 2007; 109(11): 4803 - 4805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Meadows and D. L. Bhatt Clinical Aspects of Platelet Inhibitors and Thrombus Formation Circ. Res., May 11, 2007; 100(9): 1261 - 1275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Koenen, P. von Hundelshausen, and C. Weber Inflammatory Blues Turns Velvet Skin Into Rawhide: Monocyte Rolling on Modified Endothelial PSGL-1 Arterioscler Thromb Vasc Biol, May 1, 2007; 27(5): 990 - 992. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||